Efficacy results for tasisulam versus paclitaxel revealed a response rate of 3.0 % versus 4.8 % , a median progression-free survival of 1.94 months versus 2.14 months ( P = .048 ) , and a median overall survival of 6.77 months versus 9.36 months ( P = .121 ) .